327 related articles for article (PubMed ID: 24322791)
1. Molecular breast imaging with gamma emitters.
Schillaci O; Spanu A; Danieli R; Madeddu G
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):340-51. PubMed ID: 24322791
[TBL] [Abstract][Full Text] [Related]
2. Monitoring therapy in breast cancer.
Buscombe JR
Nucl Med Commun; 2002 Jul; 23(7):619-24. PubMed ID: 12089483
[TBL] [Abstract][Full Text] [Related]
3. Breast scintigraphy today: indications and limitations.
Schillaci O; Buscombe JR
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S35-45. PubMed ID: 15103505
[TBL] [Abstract][Full Text] [Related]
4. Reduction of 99mTc-sestamibi and 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function.
Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1529-31. PubMed ID: 14579093
[TBL] [Abstract][Full Text] [Related]
5. The value of Tc-99m tetrofosmin scintimammography in the assessment of P-glycoprotein in patients with breast cancer.
Silov G; Erdoğan Z; Özdal A; Tutuş A; Tekin Y; Karaman H; Turhal Ö
Hell J Nucl Med; 2013; 16(3):218-22. PubMed ID: 24137583
[TBL] [Abstract][Full Text] [Related]
6. Tetrofosmin thyroid scintigraphy.
Klain M; Cuocolo A; Salvatore M; Maurea S
Eur J Nucl Med; 1998 Jul; 25(7):816. PubMed ID: 9741994
[No Abstract] [Full Text] [Related]
7. [99mTc]sestamibi and [99mTc]tetrofosmin in oncology: SPET and fusion imaging in lung cancer, malignant lymphomas and brain tumors.
Schillaci O; Spanu A; Madeddu G
Q J Nucl Med Mol Imaging; 2005 Jun; 49(2):133-44. PubMed ID: 16010251
[TBL] [Abstract][Full Text] [Related]
8. Molecular Breast Imaging: A Comprehensive Review.
Huppe AI; Mehta AK; Brem RF
Semin Ultrasound CT MR; 2018 Feb; 39(1):60-69. PubMed ID: 29317040
[TBL] [Abstract][Full Text] [Related]
9. Breast-specific gamma imaging (BSGI), molecular breast imaging (MBI), or scintimammography with breast-specific gamma camera.
BlueCross BlueShield Association
Technol Eval Cent Assess Program Exec Summ; 2013 Jun; 28(2):1-4. PubMed ID: 23865107
[No Abstract] [Full Text] [Related]
10. Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein.
Ballinger JR
Cancer Biother Radiopharm; 2001 Feb; 16(1):1-7. PubMed ID: 11279792
[No Abstract] [Full Text] [Related]
11. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease.
Münch G; Neverve J; Matsunari I; Schröter G; Schwaiger M
J Nucl Med; 1997 Mar; 38(3):428-32. PubMed ID: 9074532
[TBL] [Abstract][Full Text] [Related]
12. The breast cancer cell line MCF7 as a model of 99mTc-SestaMIBI, 99mTc-tetrofosmin and 99mTc-Medronate incorporation.
Molteni SN; Seregni E; Botti C; Martinetti A; Ferrari L; Crippa F; Bombardieri E
Anticancer Res; 1999; 19(1A):255-9. PubMed ID: 10226551
[TBL] [Abstract][Full Text] [Related]
13. Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.
Liu Z; Stevenson GD; Barrett HH; Furenlid LR; Wilson DW; Kastis GA; Bettan M; Woolfenden JM
Nucl Med Biol; 2005 Aug; 32(6):573-83. PubMed ID: 16026704
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin.
Gomes CM; Abrunhosa AJ; Pauwels EK; Botelho MF
Cancer Biother Radiopharm; 2009 Apr; 24(2):215-27. PubMed ID: 19409044
[TBL] [Abstract][Full Text] [Related]
15. [Breast scintigraphy].
Prats E; Razola P; García López F; Dolores Abós M; Banzo J
Rev Esp Med Nucl; 2001 Feb; 20(1):47-70. PubMed ID: 11181333
[No Abstract] [Full Text] [Related]
16. Uptake of 99mTc-MIBI and 99mTc-tetrofosmin into malignant versus nonmalignant breast cell lines.
Rodrigues M; Chehne F; Kalinowska W; Berghammer P; Zielinski C; Sinzinger H
J Nucl Med; 2000 Sep; 41(9):1495-9. PubMed ID: 10994728
[TBL] [Abstract][Full Text] [Related]
17. Effect of asiaticoside on 99mTc-tetrofosmin and 99mTc-sestamibi uptake in MCF-7 cells.
Al-Saeedi FJ; Bitar M; Pariyani S
J Nucl Med Technol; 2011 Dec; 39(4):279-83. PubMed ID: 22080437
[TBL] [Abstract][Full Text] [Related]
18. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
19. Scintimammography and single-photon emission computed tomography for postoperative image guidance for radiation treatment planning in breast cancer patients.
Piperkova E; Chavdarova L; Garanina Z; Gocheva L; Parvanova V; Tzonevska A; Dimitrova M
J BUON; 2011; 16(4):657-63. PubMed ID: 22331718
[TBL] [Abstract][Full Text] [Related]
20. Local recurrence of breast cancer demonstrated on 99mTc-MIBI scintigraphy.
Katayama N; Inoue Y; Ichikawa T; Harada M; Itoh T; Shimoyamada K; Ikeda M; Tsukune Y; Yoshikawa K
Radiat Med; 1999; 17(5):389-91. PubMed ID: 10593293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
